Korea Institute of Science and Technology

Neurobiogen Co., Ltd.

Megabiowood Co., Ltd

ChangJoon Justin Lee

Soo Jin Oh

Jong-Hyun Park

Dong Jin Kim

Ae Nim Pae

Ji Won Choi

Jun Young Heo

Yun Kyung Kim

Eui Sung Yoon

Nakwon Choi

Ki Duk Park

Yong Koo Kang

Seul Ki Yeon

Sohyun Kim

Eun Mi Hwang

Sun Joon Min

Hyun Ah Choo

Hyo Jung Song

Min Ho Nam

Dong Ho Woo

Bo Ko Jang

Eun Ji Ju

Seon Mi Jo

Soo-Jung Lee

Hyunah Choo

Eun Joo Roh

Il-Joo Cho

Daesoo Kim

Jung-Eun Park

Kye-Jung Shin

Dong-Gyu Kim

Ji Yoon Kim

Eun-Joo Roh

Soon-Hyouk Lee

Hee-jung Chun

Wan-Keun Ji

Yun-Soo Na

Bo-Eun Yoon

Sohyeon Jeong

Dong-Ho Woo

Jeong Eun Yang

Jong Hoon Jung

Jong-hyun Park

Seok Jin Hwang

Eun-Mi Hur

Sun-Kyoung Im

Seonmi Jo

Boeun Yoon

The present disclosure relates to an &#x3b1;-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Alpha-aminoamide derivative compound and pharmaceutical composition comprising same

The present disclosure relates to an apparatus and a method for manufacturing a channel-coupled scaffold. The present disclosure provides a method for manufacturing a channel-coupled scaffold, which includes: (1) a step of compressing a first elastic substrate which includes a groove on the surface of the substrate to close the groove; (2) a step of loading a scaffold composition onto the closed groove; and (3) a step of restoring the elastic substrate. The present disclosure also provides an apparatus for manufacturing a channel-coupled scaffold, which includes: a first elastic substrate which includes a groove on the surface of the substrate and onto which a scaffold composition is loaded: and a compression module which compresses the width of the groove of the elastic substrate to close it. The apparatus or method may accumulate a microchannel controlling local mass transfer, and align a collagen fiber in the scaffold at the same time.

Apparatus and method for manufacturing channel-coupled scaffold

The present disclosure relates to an &#x3b1;-aminoamide derivative compound and a pharmaceutical composition containing the same, for treating a neurodegenerative diseases.

Disclosed is a novel compound to function as a calcium-dependent chloride channel blocking agent.

Compounds as chloride channel blocking agent

The present disclosure relates to stretching apparatus and method for aligning microfibrils. Specifically, the present disclosure provides an apparatus for aligning microfibrils along a single direction, which includes: a first elastic substrate onto which a composition containing microfibrils is loaded; and a stretching module which stretches the width of the elastic substrate. In accordance with the apparatus the present disclosure, microfibrils or cells may be aligned along a particular direction simply by pulling and then releasing the elastic substrate. The present disclosure is also useful for culturing of the aligned cells because the physiological activity of the cells can be maintained and cytotoxicity can be prevented.

Stretching apparatus and method for aligning microfibrils

A pharmaceutical composition for preventing or treating a degenerative brain disease, and a method of screening a material for preventing or treating a degenerative brain disease. The method may effectively screen a prophylactic or therapeutic candidate material for preventing or treating a degenerative brain disease. A variety of degenerative brain diseases may be effectively prevented or treated using the pharmaceutical composition including a screened material for preventing or treating a degenerative brain disease.

Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same

The present invention relates to a novel phenoxypropanol derivative, represented by the structure of Chemical Formula I, and a racemate thereof, a pharmaceutically acceptable salt thereof, a solvate thereof and a hydrate thereof,  wherein * represents an (R)-form or an (S)-form, X is selected from the group consisting of hydrogen, halogen and substituted or unsubstituted straight or branched alkyl having 1 to 4 carbon atoms, and n represents the number of X and an integer of 1 to 5, wherein at least a hydrogen is substituted with halogen in the substituted linear or branched alkyl having 1 to 4 carbon atoms. The derivative can be used for blocking T-type calcium channel and/or TREK channel, and for preventing and/or treating T-type calcium channel- and/or TREK channel-associated diseases.

Phenoxypropanol derivative and pharmaceutical composition including the same

A GABA (gamma-aminobutyric acid) release-inhibiting agent in the cerebellum and a composition for treating pathological symptoms caused by over-release of GABA in the cerebellum, each comprising a Bestrophin 1 (Best1) channel inhibitor as an active ingredient; a GABA release-promoting agent in the cerebellum and a composition for treating pathological symptoms caused by the deficit of GABA in the cerebellum, each comprising a Best1 channel activator as an active ingredient; and a method for screening a GABA release-regulating agent in the cerebellum, which uses Best1 channel as target, are provided.

GABA release-regulating agent in cerebellum

The present invention investigate the two modes of glutamate release and the releasing rate of glutamate, and thus can provide a useful technique for neuron protection and acceleration of neurotransmission by controlling the glutamate release in astroctye. Thus, the present invention provides an inhibitor of the fast-mode release and/or the slow-mode release of astrocytic glutamate, a screening method of the inhibitor and a pharmaceutical composition or method of ameliorating, preventing and/or treating the disease associated with the over-release of glutamate via the Ca-activated anion channel, with the inhibition of fast-mode glutamate release.

Method for screening a glutamate release inhibitor in an astrocyte

The present invention relates to a novel use of a transfected cell as a biosensor, wherein the transfected cell expresses a receptor specific to a bio-signal transmitter, and a highly sensitive detector and a highly sensitive detecting method of a bio-signal transmitter using the biosensor. The bio-signal transmitter detecting technique according to the present invention has an advantage of being applied to a sniffer-patch method, and is capable of providing millisecond time resolution for detecting nanomolar levels of the bio-signal transmitter to be detected.

Ultra sensitive biosensor for detecting bio-signal transmitters, and detector and detecting method using the same

Growing community of inventors

Seoul, South Korea

ChangJoon Justin Lee